The Development of Whole Sporozoite Vaccines for Plasmodium falciparum Malaria DOI Creative Commons

Leslie S. Itsara,

Yaxian Zhou,

Julie Do

и другие.

Frontiers in Immunology, Год журнала: 2018, Номер 9

Опубликована: Дек. 11, 2018

Each year malaria kills hundreds of thousands people and infects millions despite current control measures. An effective vaccine will likely be necessary to aid in eradication. Vaccination using whole sporozoites provides an increased repertoire immunogens compared subunit vaccines across at least two life cycle stages the parasite, extracellular sporozoite, intracellular liver stage. Three potential sporozoite approaches are under development include genetically attenuated parasites, radiation sporozoites, wild-type administered combination with chemoprophylaxis. Pre-clinical clinical studies have demonstrated immunogenicity, including humoral cellular immunity a range efficacy that depends on pre-exposure vaccinated individuals. While can provide protection against some cases, more recent malaria-endemic regions demonstrate need for improvements. Moreover, challenges remain manufacturing large quantities commercialization. A promising solution challenge is vitro culturing methodology, which has been described several Plasmodium species, major disease-causing human falciparum. Here, we review immunogenicity platforms production.

Язык: Английский

Malaria Vaccines: Recent Advances and New Horizons DOI Creative Commons
Simon J. Draper,

Brandon K. Sack,

C. Richter King

и другие.

Cell Host & Microbe, Год журнала: 2018, Номер 24(1), С. 43 - 56

Опубликована: Июль 1, 2018

The development of highly effective and durable vaccines against the human malaria parasites Plasmodium falciparum P. vivax remains a key priority. Decades endeavor have taught that achieving this goal will be challenging; however, recent innovation in vaccine research diverse pipeline novel candidates for clinical assessment provides optimism. With first-generation pre-erythrocytic aiming licensure coming years, it is important to reflect on how next-generation approaches can improve their success. Here we review latest seek prevent infection, disease, transmission highlight some major underlying immunological molecular mechanisms protection. synthesis rational antigen selection, immunogen design, immunization strategies induce quantitatively qualitatively improved immune effector offers promise sustained high-level

Язык: Английский

Процитировано

305
A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite DOI
Neville K. Kisalu, Azza H. Idris, Connor Weidle

и другие.

Nature Medicine, Год журнала: 2018, Номер 24(4), С. 408 - 416

Опубликована: Март 19, 2018

Язык: Английский

Процитировано

276
Challenges and strategies for developing efficacious and long-lasting malaria vaccines DOI Creative Commons
James G. Beeson, Liriye Kurtovic, Carlota Dobaño

и другие.

Science Translational Medicine, Год журнала: 2019, Номер 11(474)

Опубликована: Янв. 9, 2019

New knowledge and strategies are emerging to enable the development of an efficacious long-lasting vaccine against malaria.

Язык: Английский

Процитировано

183
A replication competent Plasmodium falciparum parasite completely attenuated by dual gene deletion DOI Creative Commons
Debashree Goswami, Hardik Patel, William Betz

и другие.

EMBO Molecular Medicine, Год журнала: 2024, Номер 16(4), С. 723 - 754

Опубликована: Март 21, 2024

Язык: Английский

Процитировано

19
Malaria prevention: from immunological concepts to effective vaccines and protective antibodies DOI Creative Commons
Ian A. Cockburn, Robert A. Seder

Nature Immunology, Год журнала: 2018, Номер 19(11), С. 1199 - 1211

Опубликована: Окт. 12, 2018

Development of a malaria vaccine remains critical priority to decrease clinical disease and mortality facilitate eradication. Accordingly, RTS,S, protein-subunit vaccine, has completed phase III trials confers ~30% protection against infection over 4 years. Whole-attenuated-sporozoite viral-subunit vaccines induce between 20% 100% controlled human infection, but there is limited published evidence date for durable, high-level efficacy (>50%) natural exposure. Importantly, fundamental scientific advances related the potency, durability, breadth location immune responses will be required improving with these other approaches. In this Review, we focus on current understanding immunological mechanisms from animal models studies, how data should inform development next-generation vaccines. Furthermore, introduce concept using passive immunization monoclonal antibodies as new approach prevent eliminate malaria.

Язык: Английский

Процитировано

156
Controlled Human Malaria Infection: Applications, Advances, and Challenges DOI Open Access
Danielle I. Stanisic, James McCarthy, Michael F. Good

и другие.

Infection and Immunity, Год журнала: 2017, Номер 86(1)

Опубликована: Сен. 19, 2017

Controlled human malaria infection (CHMI) entails deliberate with parasites either by mosquito bite or direct injection of sporozoites parasitized erythrocytes. When required, the resulting blood-stage is curtailed administration antimalarial drugs. Inducing a via inoculation infected blood was first used as treatment (malariotherapy) for neurosyphilis in Europe and United States early 1900s. More recently, CHMI has been applied to fields vaccine drug development, where it evaluate products well-controlled early-phase proof-of-concept clinical studies, thus facilitating progression only most promising candidates further evaluation areas endemic. infections have also immunize against infection. Historically, studies restricted need access insectaries housing mosquitoes suitable malaria-infected individuals. Evaluation constrained these availability limited number Plasmodium falciparum isolates. Recent advances included cryopreservation sporozoites, manufacture well-characterized genetically distinct cultured cell banks infection, vivax-specific reagents. These will help accelerate development making reagents more widely accessible enabling rigorous multiple parasite strains species. Here we discuss different applications CHMI, recent use ongoing challenges consideration.

Язык: Английский

Процитировано

134
A Specific PfEMP1 Is Expressed in P. falciparum Sporozoites and Plays a Role in Hepatocyte Infection DOI Creative Commons
Gigliola Zanghì, Shruthi Sridhar Vembar, Sebastian Baumgarten

и другие.

Cell Reports, Год журнала: 2018, Номер 22(11), С. 2951 - 2963

Опубликована: Март 1, 2018

Heterochromatin plays a central role in the process of immune evasion, pathogenesis, and transmission malaria parasite Plasmodium falciparum during blood stage infection. Here, we use ChIP sequencing to demonstrate that sporozoites from mosquito salivary glands expand heterochromatin at subtelomeric regions silence blood-stage-specific genes. Our data also revealed enrichment is predictive transcription status clonally variant genes members mediate cytoadhesion parasites. A specific member (here called NF54varsporo) var gene family remains euchromatic, resultant PfEMP1 (NF54_SpzPfEMP1) expressed sporozoite surface. NF54_SpzPfEMP1-specific antibodies efficiently block hepatocyte infection strain-specific manner. Furthermore, human volunteers immunized with infective developed against NF54_SpzPfEMP1. Overall, show epigenetic signature reset stages. Moreover, identification highly relevant for vaccine design based on sporozoites.

Язык: Английский

Процитировано

114
Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity DOI
Agnes Mwakingwe-Omari, Sara A. Healy,

Jacquelyn Lane

и другие.

Nature, Год журнала: 2021, Номер 595(7866), С. 289 - 294

Опубликована: Июнь 30, 2021

Язык: Английский

Процитировано

95
Advances in malaria vaccine development: report from the 2017 malaria vaccine symposium DOI Creative Commons
Camila H. Coelho, Justin Doritchamou, Irfan Zaidi

и другие.

npj Vaccines, Год журнала: 2017, Номер 2(1)

Опубликована: Ноя. 16, 2017

The Malaria Vaccine Symposium occurred at Johns Hopkins University in Baltimore, MD, USA on April 25th, 2017, coinciding with World Day and the WHO announcement that RTS,S malaria vaccine would begin pilot implementation programs Ghana, Kenya, Malawi 2018. Scientists from several disciplines reported progress an array of concepts product candidates, including pre-erythrocytic vaccines prevent infection, blood-stage limit infection disease, transmission-blocking interrupt spread infection. Other speakers highlighted immunological genetic considerations must be addressed by vaccinologists to yield most efficacious vaccines. Here, we highlight advances vaccinology were symposium.

Язык: Английский

Процитировано

89
Sporozoite immunization: innovative translational science to support the fight against malaria DOI Creative Commons
Thomas L. Richie, L. W. Preston Church,

Tooba Murshedkar

и другие.

Expert Review of Vaccines, Год журнала: 2023, Номер 22(1), С. 964 - 1007

Опубликована: Авг. 11, 2023

Malaria, a devastating febrile illness caused by protozoan parasites, sickened 247,000,000 people in 2021 and killed 619,000, mostly children pregnant women sub-Saharan Africa. A highly effective vaccine is urgently needed, especially for

Язык: Английский

Процитировано

30